SUBSCRIBERS

DBS retains 'buy' on IHH with S$2.32 target despite US lawsuit

Its analysts note IHH is confident it has strong grounds to seek dismissal for Emqore's claims

Tessa Oh
Published Fri, Jan 7, 2022 · 09:50 PM

    DeeperDive is a beta AI feature. Refer to full articles for the facts.

    Singapore

    IT IS premature to determine the estimated potential liability that the legal spat between US fund Emqore Envesecure Private Capital Trust and IHH Healthcare will have on the latter, as it involves a number of defendants and non-party defendants, said DBS Group Research.

    Emqore is seeking over US$6.5 billion in damages in a lawsuit against the Mainboard-listed company and other defendants.

    Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.

    Copyright SPH Media. All rights reserved.